Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02606305
Recruitment Status : Active, not recruiting
First Posted : November 17, 2015
Last Update Posted : March 3, 2021
Sponsor:
Information provided by (Responsible Party):
ImmunoGen, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 8, 2021
Estimated Study Completion Date : March 8, 2021